Skip to main content

Table 3 Factors associated with non-invasive therapy by age category for the total sample and stratified by type of AMI

From: Predictors of non-invasive therapy and 28-day-case fatality in elderly compared to younger patients with acute myocardial infarction: an observational study from the MONICA/KORA Myocardial Infarction Registry

  Age category
25–64 years 65–74 years 75–84 years
OR [95 % CI] p Value OR [95 % CI] p Value OR [95 % CI] p Value
Total sample (n = 3452)a (n = 1324) (n = 1077) (n = 1051)
 Sex (women vs. men) 1.28 [0.80–2.06] 0.30 1.80 [1.24–2.61] 0.002 1.38 [1.03–1.85] 0.03
 Type of AMI (NSTEMI vs. STEMI) 3.07 [1.81–5.20] <0.0001 2.54 [1.59–4.05] <0.0001 2.36 [1.59–3.51] <0.0001
 Type of AMI (BBB vs. STEMI) 4.22 [1.76–10.1] 0.001 2.01 [1.05–3.84] 0.03 2.60 [1.58–4.26] 0.001
 Prior stroke (yes vs. no) 2.97 [1.40–6.30] 0.005 1.91 [1.17–3.13] 0.01 1.87 [1.27–2.75] 0.002
 Renal dysfunction (yes vs. no) 2.27 [1.06–4.90] 0.04 1.59 [1.03–2.45] 0.04 1.35 [0.97–1.87] 0.07
 Prior MI (yes vs. no) 2.08 [1.27–3.41] 0.004 2.00 [1.35–2.95] 0.001 1.27 [0.89–1.81] 0.18
 LVEF (LVEF ≤ 30 % vs. LVEF > 30 %) 3.28 [1.60–6.71] 0.001 1.85 [1.02–3.35] 0.04 2.02 [1.30–3.14] 0.002
 LVEF (LVEF n/mb vs. LVEF > 30 %) 6.58 [4.05–10.7] <0.0001 5.03 [3.32–7.63] <0.0001 6.10 [4.27–8.73] <0.0001
 History of hyperlipidemia (yes vs. no) 0.52 [0.34–0.80] 0.003 0.63 [0.44–0.90] 0.01 0.67 [0.49–0.91] 0.01
 History of COPD (yes vs. no) 1.89 [0.87–4.13] 0.11 2.26 [1.34–3.81] 0.002 0.83 [0.50–1.39] 0.48
 Peak serum CPK level (U/l) (continuous) 1.00 [1.00–1.00] 0.003 1.00 [1.00–1.00] 0.04 1.00 [1.00–1.00] <0.0001
STEMI (n = 1292) (n = 625) (n = 369) (n = 298)
 Sex (women vs. men) n/ac 2.35 [1.06–5.21] 0.04 n/ac
 Prior stroke (yes vs. no) 11.2 [2.58–48.7] 0.001 n/ac n/ac
 LVEF (LVEF ≤ 30 % vs. LVEF > 30 %) 3.71 [1.01–13.6] 0.05 2.36 [0.74–7.54] 0.15 1.53 [0.58–4.03] 0.39
 LVEF (LVEF n/mb vs. LVEF > 30 %) 4.13 [1.22–14.0] 0.02 3.90 [1.30–11.7] 0.02 13.0 [5.72–29.3] <0.0001
NSTEMI (n = 1838) (n = 647) (n = 603) (n = 588)
 Sex (women vs. men) n/ac 1.63 [1.04–2.53] 0.03 n/ac  
 Prior stroke (yes vs. no) n/ac n/ac 2.15 [1.34–3.46] 0.002
 Renal dysfunction (yes vs. no) 2.76 [1.18–6.45] 0.02 1.80 [1.09–2.99] 0.02 n/ac
 Prior MI (yes vs. no) 1.81 [1.03–3.18] 0.04 2.04 [1.30–3.21] 0.002 n/ac
 LVEF (LVEF ≤ 30 % vs. LVEF > 30 %) 3.08 [1.15–8.22] 0.03 1.88 [0.86–4.13] 0.12 3.19 [1.75–5.80] 0.001
 LVEF (LVEF n/mb vs. LVEF > 30 %) 6.24 [3.56–10.9] <0.0001 5.04 [3.12–8.16] <0.0001 5.49 [3.54–8.50] <0.0001
 History of hyperlipidemia (yes vs. no) 0.52 [0.32–0.85] 0.01 n/ac 0.51 [0.35–0.74] 0.001
 History of COPD (yes vs. no) 2.57 [1.05–6.32] 0.04 2.11 [1.16–3.85] 0.01 n/ac
 Peak serum CPK level (U/l) (continuous) 1.00 [1.00–1.00] 0.001 n/ac 1.00 [1.00–1.00] 0.005
BBB (n = 330) (n = 53) (n = 111) (n = 165)
 Prior MI (yes vs. no) 9.18 [1.62–51.9] 0.01d 3.17 [1.10–9.12] 0.03 n/ac
 Renal dysfunction (yes vs. no) 18.8 [1.04–340.0] 0.05d n/ac n/ac
 History of hypertension (yes vs. no) 0.11 [0.02–0.68] 0.02d n/ac n/ac
 LVEF (LVEF ≤ 30 % vs. LVEF > 30 %) N/Ae 2.41 [0.65–8.99] 0.19 1.14 [0.46–2.83] 0.79
 LVEF (LVEF n/mb vs. LVEF > 30 %) N/Ae 10.5 [3.27–33.7] <0.0001 9.44 [3.89–22.9] <0.0001
 Peak serum CPK level (U/l) (continuous n/ac n/ac 1.00 [1.00–1.00] 0.01
  1. The multivariable analysis included as explanatory variables sex, type of AMI (‘dummy’-coded), LVEF (‘dummy’-coded), renal dysfunction, prior stroke, prior MI, history of diabetes, hypertension, hyperlipidemia, angina pectoris and COPD, pre-hospital time, and peak serum CPK level. In the total sample, variables which meet the 0.05 significance level in at least one age category were included and presented. For the sub-samples by type of AMI only the significant factors in that sub-sample model (forward stepwise selection technique) were included and presented
  2. OR odds ratio, CI confidence interval, AMI acute myocardial infarction, STEMI ST-elevation myocardial infarction, NSTEMI non-ST-elevation myocardial infarction, BBB bundle branch block, LVEF left ventricular ejection fraction, COPD chronic obstructive pulmonary disease, CPK creatine phosphokinase
  3. a As 23 patients had no data on peak serum CPK level, the total sample size was 3452 instead of 3475
  4. b n/m, LVEF were not assessed or missing
  5. c n/a, OR and p value were not applicable because the analyzed variable did not meet the 0.05 significance level for entry into the model of the sub-sample
  6. d P value and OR were assessed in a separate model without the variables regarding LVEF
  7. e N/A, not applicable due to quasi-complete separation of data points detected when ‘LVEF’ was included